Pono Capital Two, Inc.
PTWOW
NASDAQ Global Market0.07
USD
+0.00
- -
CIK
0001930313
ISIN
US73245B1153
CUSIP
73245B115
Return %
Stock
S&P500
1Y
55.65
26.53
3Y
46.00
76.60
5Y
46.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Darryl S. Nakamoto
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 643 Ilalo Street Honolulu HI United States of America 96816
- CIK
- 0001930313
- Similar Companies
- Business
- Pono Capital Two, Inc. (NASDAQ:PTWOW) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant independent operations other than identifying and executing a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target businesses, particularly those in Japan and tech-enabled sectors. Incorporated in Delaware in 2022 and headquartered at 643 Ilalo St. #102, Honolulu, Hawaii, the company is a subsidiary of sponsor Mehana Capital LLC and raised approximately $115 million in its initial public offering in August 2022, with units (PTWOU), Class A common stock (PTWO), and warrants (PTWOW) listed on Nasdaq. It targets mergers with businesses across diverse sectors, leveraging capital from its trust to pursue value-creation opportunities through due diligence, acquisition, and post-merger integration. In a major development completed on September 17, 2024, Pono Capital Two finalized a reverse merger business combination with SBC Medical Group Holdings Incorporated, a global provider of management services and products to cosmetic treatment centers primarily in Japan. Following stockholder approval on August 23, 2024, Pono changed its name to SBC Medical Group Holdings Incorporated (NASDAQ:SBC), with SBC Medical surviving as the primary operating entity; the combined company now trades under SBC for common stock and warrants, while PTWOW warrants persist separately. This transaction, initially valued at approximately $1.2 billion enterprise value and announced in stages from December 2022 onward, enables SBC Medical's expansion into new clinics, product lines, U.S. and Asian markets, medical tourism, and technologies like AI-driven simulators for training in aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA hair restoration, ophthalmology, and general care. Through the post-merger entity, SBC Medical offers comprehensive franchise management services including advertising and marketing across social media; staff recruitment and training; customer booking reservations; clinic facility rentals, construction, and design; resale of medical equipment and consumables; cosmetics provisioning; licensing of medical technologies and brands; IT software solutions for online consulting; and customer reward programs. The group operates a diverse clinic portfolio in Japan with global ambitions, providing scalable, profitable operations in elective and insured medical treatments via brands focused on safe cosmetic procedures and multidisciplinary care. Recent financials reflect net sales of around $47 million and net profit of $21 million, supporting ongoing investments in organic and inorganic growth.